Sofgen Pharma

Sofgen Pharma Current Assets

Delisted·Sep 1, 2026

The Current Assets of Sofgen Pharma (PROCF) as of Oct 15, 2026 is 82.57 M USD. In the previous year, Current Assets was 104.74 M USD — a change of -21.17% (lower).

Current Assets

82.57 MUSD

YoY

-21.17%

Last updated:

Current Assets of Sofgen Pharma is 2024 82.57 M USD. Current Assets of Sofgen Pharma was 2023 104.74 M USD. It decreases by -21.17% lower compared to the previous year.

The Sofgen Pharma Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2020
184.70 M USD
Jan 1, 2021
228.09 M USD
Jan 1, 2022
257.41 M USD
Jan 1, 2023
104.74 M USD
Jan 1, 2024
82.57 M USD
The Sofgen Pharma Current Assets history
YEARCurrent AssetsYoY
82.57 MUSD-21.17%
104.74 MUSD-59.31%
257.41 MUSD+12.85%
228.09 MUSD+23.49%
184.70 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sofgen Pharma Stock analysis

What does Sofgen Pharma do? Sofgen Pharma SA, listed under the ticker PROCF with ISIN LU2376511205, is a pharmaceutical company headquartered in Luxembourg. The company operates within the Health Care sector, specifically in the Pharmaceuticals industry. Sofgen Pharma employs approximately 5,500 people and completed its initial public offering on December 9, 2019. The company's website is https://www.procapsgroup.com/. Sofgen Pharma SA develops, manufactures, and sells prescription drugs and products featuring unique combinations and pharmaceutical forms, alongside nutritional supplements such as omega-3 fish oils and high-potency clinical compounds. The company organizes its operations through five business units: Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics focuses on diabetes solutions. Farma Procaps is involved in formulating, manufacturing, and marketing branded prescription drugs in Latin America. Softi Gel offers contract drug development and manufacturing services to other pharmaceutical companies. Vital Care specializes in developing, manufacturing, and marketing consumer healthcare products. Clinical Specialties is dedicated to the development, manufacturing, and marketing of complex drugs. The company's business model emphasizes specialized pharmaceutical solutions and consumer health products, with a global operational footprint. Sofgen Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sofgen Pharma stock

Current Assets of Sofgen Pharma is 82.57 M USD in 2024.

Current Assets of Sofgen Pharma changed from 104.74 M USD to 82.57 M USD, representing a -21.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Sofgen Pharma since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Sofgen Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Sofgen Pharma

All Key Metrics — Sofgen Pharma